GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Stock Based Compensation

Halberd (Halberd) Stock Based Compensation : $0.00 Mil (TTM As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Stock Based Compensation?

Halberd's Stock Based Compensation for the six months ended in Jul. 2023 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.


Halberd Stock Based Compensation Historical Data

The historical data trend for Halberd's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Stock Based Compensation Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Stock Based Compensation
- - -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Stock Based Compensation - - -

Halberd Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.


Halberd Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Halberd's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236